Growth hormone replacement in patients with a history of malignancy: a review of the literature and best practice for offering treatment.

Growth hormone replacement in patients with a history of malignancy: a review of the literature and best practice for offering treatment. Expert Rev Endocrinol Metab. 2015 May;10(3):319-326 Authors: Yuen KC, Popovic V Abstract Previous studies have implicated the growth hormone (GH)/IGF-I axis as an important mediator of cancer risk in humans and animals. Evidence supporting this notion is derived from animal studies, epidemiological observations, patients with acromegaly and from therapeutic manipulation of GH and IGF-I actions. Therefore, the use of GH therapy in patients with a history of malignancy raises hypothetical safety concerns. Reassuringly, GH therapy in childhood cancer survivors has not been confirmed to increase the cancer risk. Conversely, the risk of occurrence of a second neoplasm may be increased, with meningiomas being the most common tumor. In light of these findings, we propose considering GH therapy to be based on each individual's circumstance and commenced at least 2 years after cancer remission is achieved with close monitoring during therapy. More long-term data are needed on the safety of GH replacement therapy in GH-deficient adults with a history of malignancy. PMID: 30298774 [PubMed]
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research

Related Links:

Authors: Li T, Han J, Jia L, Hu X, Chen L, Wang Y Abstract A change in the metabolic flux of glucose from mitochondrial oxidative phosphorylation (OXPHOS) to aerobic glycolysis is regarded as one hallmark of cancer. However, the mechanisms underlying the metabolic switch between aerobic glycolysis and OXPHOS are unclear. Here we show that the M2 isoform of pyruvate kinase (PKM2), one of the rate-limiting enzymes in glycolysis, interacts with mitofusin 2 (MFN2), a key regulator of mitochondrial fusion, to promote mitochondrial fusion and OXPHOS, and attenuate glycolysis. mTOR increases the PKM2:MFN2 interaction by p...
Source: Protein and Cell - Category: Cytology Tags: Protein Cell Source Type: research
In conclusion, CD133 promoted the upregulation of CSC/TSC-related genes in glioma cells, while enhancing the neurosphere-forming ability and in-vivo oncogenicity. PMID: 30891998 [PubMed - as supplied by publisher]
Source: Journal of Biological Regulators and Homeostatic Agents - Category: Biomedical Science Tags: J Biol Regul Homeost Agents Source Type: research
In this study, several cerasome-forming lipoamino acids (CFLA) were synthesized and used as structural blocks for cerasome preparation. Pure cerasomes which contained only CFLA, and mixed cerasomes based on a mixture of CFLA with a disintegrating dipalmitoylphosphatidylcholine (DPPC) lipid were fabricated and characterized in terms of morphology, mean size, ζ-potential, stability at storage. All obtained cerasome samples were found to be much more stable at storage than conventional liposomes (120 and 10 days, respectively). The cerasomes were loaded with doxorubicin (DOX) and tested in vitro using human breast aden...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Taxol is a common chemotherapy (CTX) drug that is associated with the development of neuropathy. Paclitaxel-induced peripheral neuropathy (PIPN) is the dose limiting toxicity of this CTX drug. Paclitaxel exerts its therapeutic effect by binding to β-tubulin, which interferes with microtubule dynamics and results in microtubule stabilization, mitotic arrest, and apoptosis of cancer cells. However, microtubules are critical for axonal function and for the transport of essential organelles to distal nerve endings.
Source: The Journal of Pain - Category: Materials Science Authors: Source Type: research
The objectives of this work were to study 1) effects of oxaliplatin on membrane excitability in Isoletcin B4-positive and –negative (IB4+ and IB4-) subpopulations of dorsal root ganglion (DRG), and 2) targeting oxaliplatin-induced membrane hyperexcitability to relief neuropathic pain.
Source: The Journal of Pain - Category: Materials Science Authors: Source Type: research
Tongue cancer patients suffer severe, chronic pain driven by oral cancer-induced activation of sensory neurons innervating the oral cavity. However, the impact of sensory neurotransmission on oral carcinogenesis is understudied. Local neurotransmitter release from sensory neurons innervating the cancer has been linked to cancer growth and immune suppression. We hypothesize that oral cancer-induced neurotransmitter release from trigeminal sensory neurons (TGNs) promotes oral cancer proliferation and suppresses the immune response.
Source: The Journal of Pain - Category: Materials Science Authors: Source Type: research
The experience of cancer pain is poorly understood from the perspective of African Americans, who experience higher levels of pain, more pain-related distress, and poorer function than Caucasians. Perceived control over pain has been shown to lead to decreased pain and distress and improved functional status. Perceived control over pain may play a role in the adequacy of prescriptions received by African American patients with cancer pain. The purpose of this study is to investigate the relationship between factors affecting analgesic prescriptions and perceived control over pain in African Americans with cancer pain.
Source: The Journal of Pain - Category: Materials Science Authors: Source Type: research
Microduplications of the GPR101 gene (located on chromosome Xq26.3 and encodes a G-protein coupled receptor) can result in an excess of growth hormone causing gigantism, that has an onset in early childhood. It is also associated with the growth of sporadic growth hormone producing adenomas in some patients with acromegaly.Current therapies (such as surgical resection of tumors or treatment with somatostatin analogs) for acromegaly, gigantism and other disorders of pituitary hormone hypersecretion can be ineffective, thereby creating a need for alternative therapies in this space.The inventors at theEunice Kennedy Shriver ...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Publication date: Available online 22 February 2017 Source:Best Practice & Research Clinical Endocrinology & Metabolism Author(s): S. Pekic, M. Stojanovic, V. Popovic Growth hormone (GH) replacement in GH deficient (GHD) children secures normal linear growth, while in GHD adults it improves metabolic status, body composition and quality of life. Safety of GH treatment is an important issue in particular concerning the controversy of potential cancer risk. Unlike in congenital IGF-1 deficiency, there is no complete protection against cancer in GHD patients. Important modifiable risk factors in GHD patients are obes...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - Category: Endocrinology Source Type: research
X-linked acrogigantism (X-LAG) syndrome is a newly described form of inheritable pituitary gigantism that begins in early childhood and is usually associated with markedly elevated GH and prolactin secretion by mixed pituitary adenomas/hyperplasia. Microduplications on chromosome Xq26.3 including the GPR101 gene cause X-LAG syndrome. In individual cases random GHRH levels have been elevated. We performed a series of hormonal profiles in a young female sporadic X-LAG syndrome patient and subsequently undertook in vitro studies of primary pituitary tumor culture following neurosurgical resection. The patient demonstrated con...
Source: Endocrine-Related Cancer - Category: Endocrinology Authors: Tags: Research Source Type: research
More News: Acromegaly | Cancer | Cancer & Oncology | Childhood Cancer | Endocrinology | Epidemiology | Hormones | Men | Study